Literature DB >> 434489

Orally administered dantrolene for prophylaxis of malignant hyperthermia.

S K Pandit, S P Kothary, P J Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 434489     DOI： 10.1097/00000542-197902000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  4 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

2.  Masseter contracture and tachycardia causing termination of anesthesia.

Authors:  B W Burger; E Malsch; B W Mayer
Journal:  Anesth Prog       Date:  1984 Nov-Dec

3.  Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.

Authors:  Barbara W Brandom; Marilyn Green Larach; Min-Shue Alvin Chen; Michael C Young
Journal:  Anesth Analg       Date:  2011-03-03       Impact factor: 5.108

Review 4.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.